Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
CTSO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $1.61
Previous CloseN/A
Volume86.19K
Average Volume (3M)127.81K
Market Cap
$58.12M
Enterprise Value$102.80M
Total Cash (Recent Filing)$22.37M
Total Debt (Recent Filing)$9.94M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 06, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding54,830,147
10 Day Avg. Volume189,696
30 Day Avg. Volume127,812
Standard Deviation0.23
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.54
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-5.99
Forecast
1Y Price Target
$10.00Price Target Upside870.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Cytosorbents News
PremiumPre-Earnings
Is CTSO a Buy, Before Earnings?
PremiumCompany Announcements
CytoSorbents Boosts Liquidity with Warrant Expiration
PremiumCompany Announcements
Cytosorbents Boosts Liquidity with Successful Rights Offering
---
Bulls Say, Bears Say
Bulls Say
International ExpansionThe company successfully launched PuriFi, a novel hemoperfusion pump, in select international markets.
Product LaunchThe launch of PuriFi, a novel hemoperfusion pump, continues to go well with many evaluations ongoing.
Regulatory ProgressThe FDA has accepted the 510(k) De Novo application for DrugSorb-ATR, and it is now under review.
Bears Say
Gross Margin DeclineThe company's blended product gross margin for the quarter decreased to 61%, compared to 72% in 3Q23 and 75% in 2Q24.
Net LossThe company reported a net loss of $0.08 per share.
Revenue MissThe company reported total revenues of $9.4M for the quarter, compared to consensus estimated revenue of $10.4M.
---
Ownership Overview
6.77% Insiders
6.87% Mutual Funds
16.91% Other Institutional Investors
66.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.70 and its highest was $1.61 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $58.12M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Mar 06, 2025 which is in 2 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Nov 07, 2024. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.025.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.05.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 54,830,147 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went down -17.778%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
---
Cytosorbents Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (870.87% Upside)
$10.00 (870.87% Upside)
Hedge Fund Trend
Decreased
By 349.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $79.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.27%
12-Months-Change
Fundamentals
Return on Equity
-118.50%
Trailing 12-Months
Asset Growth
0.48%
Trailing 12-Months
Company Description
Cytosorbents Corp
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
---
CTSO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with strong revenue growth, significant reductions in operating expenses, and important regulatory progress for DrugSorb ATR. However, the decline in gross margins and decreased grant revenue are notable challenges. The sentiment leans towards optimism with strategic advancements in product development and market readiness.Read More>---
CTSO Stock 12 Month Forecast
Average Price Target
$10.00
▲(870.87% Upside)
Technical Analysis
Best Analysts Covering CTSO
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
+4.24%
reiterated a buy rating 2 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of +4.24% per trade.
---